Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Anaerobic protozoan DNA refers to the deoxyribonucleic acid found within the nuclei of anaerobic parasitic protozoa such as *Entamoeba histolytica*, *Giardia lamblia*, and *Trichomonas vaginalis*. This DNA encodes all genetic information necessary for the survival, metabolism, and reproduction of these unicellular eukaryotes[1][2]. The structure and function of this DNA are similar to that found in other eukaryotes, being organized into chromosomes within a membrane-bound nucleus[1]. In some species, there are distinct nuclear types (e.g., micronucleus and macronucleus in ciliates), each with specialized roles[1]. While DNA itself is not a therapeutic target, it is the molecular substrate for several anti-protozoal drugs. For example, metronidazole acts by causing strand breaks or chemical modifications to the parasite's DNA under anaerobic conditions—this mechanism underlies its effectiveness against infections caused by these organisms[2]. However, "anaerobic protozoan DNA" is not a canonical drug target like an enzyme or receptor; rather, it is a general molecular component present in all living cells. There may be confusion or incorrectness in listing "anaerobic protozoan DNA" as a discrete therapeutic target. The term lacks specificity—it does not refer to a particular gene product or protein but instead denotes all nuclear genetic material from this group of organisms. Therefore, while drugs can interact with this molecule class non-selectively (e.g., via genotoxic mechanisms), it should not be considered a standard pharmacological target. In summary: > “Anaerobic protozoan DNA” describes the total genomic content within pathogenic anaerobic protists but does not represent an individual druggable entity such as an enzyme or receptor. Its inclusion as a therapeutic target is imprecise; more accurate targets would be specific enzymes involved in nucleic acid synthesis or repair unique to these pathogens[2][1]. If you need structured data on actual validated targets within these organisms—such as pyruvate:ferredoxin oxidoreductase (PFOR) or other metabolic enzymes—please specify further.
DNA damage and inhibition of nucleic acid synthesis by nitroimidazole drugs in anaerobic conditions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Anaerobic protozoan DNA.